Recent Articles from GlobeNewswire

DUBAI, United Arab Emirates, March 11, 2026 (GLOBE NEWSWIRE) -- tpay, the leading payment connector in the Middle East, Turkey, and Africa (META), continues to gain recognition following its recent win at the MEFFYS 2026 Awards in the Payment & Commerce category.

Collaboration aligned to Canada’s Defence Industrial Strategy will accelerate sovereign autonomous navigation systems for GPS-denied and Arctic environments

CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced the first person dosed in a Phase 2 clinical trial in isolated dystonia with VIM0423, a potential first-in-class oral therapy, and the extension of its Series A financing to $100M. The round included participation from new investor Frazier Life Sciences (FLS) and existing investors Atlas Venture, Access Industries, and Canaan Partners. Joe Cabral, Partner at FLS, will join Vima’s Board of Directors. The financing will enable the company to complete two Phase 2 trials with VIM0423 for isolated dystonia and Parkinson’s disease. The company expects to initiate a Phase 2 trial in Parkinson’s disease in mid-2026, with topline data from both trials anticipated in the first half of 2027.

Pub Beer introduces a 99‑calorie American‑style light lager at 4% ABV

COLUMBUS, Ohio, March 11, 2026 (GLOBE NEWSWIRE) -- Bread Financial® Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending, and saving solutions to millions of U.S. consumers, provided a performance update. The following tables present the Company’s Net principal loss rate and Delinquency rate for the periods indicated:

Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027

New integration helps HR teams reduce administrative burden, maintain data accuracy, and scale international hiring with confidence

HOLLY, Mich., March 11, 2026 (GLOBE NEWSWIRE) -- Leading vehicle additive manufacturer Rislone received the prestigious AutoZone Mexico WITTDTJR® award at the retailer’s recent Mexico Summit. The award recognizes Rislone’s strong customer commitment and dedication to AutoZone’s success.

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease –

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Flutter Entertainment plc (“Flutter”) (NYSE:FLUT; LSE:FLTR), the world's leading online sports betting and iGaming operator, announces that it has entered into non-discretionary arrangements with Goldman Sachs & Co. LLC to repurchase ordinary shares on Flutter’s behalf for an aggregate maximum consideration of up to $250 million on the New York Stock Exchange (the “Buyback”).

ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from a Pharvaris-sponsored non-interventional, mixed methods, real-world study assessing the patient experience during acute HAE attacks across alternative endpoints used in clinical studies have been published in Clinical Reviews in Allergy & Immunology. The study evaluated the patient experience with HAE attack manifestations, and what constitutes meaningful changes in those manifestations, to support the inclusion of meaningful endpoints in clinical studies for on-demand treatment (ODT) of HAE attacks, such as RAPIDe-3 (NCT06343779).

New property performance metrics dashboard gives rental owners financial X-ray vision into NOI, cash flow, cash-on-cash return, and equity

Platform Rebrand of Researgency.ai; First Purpose-Built AI Agent for Biotech Expected to Ship Within Two Weeks

Chesapeake, VA , March 11, 2026 (GLOBE NEWSWIRE) -- Unchained for Pet Lovers, a premium home-care brand focused on solving stubborn pet messes, is bringing a professional-grade alternative to the consumer pet-cleaning market with its flagship product Unchained Pet Stain & Odor Remover. Designed for households that want strong cleaning performance while avoiding harsh chemical formulations often associated with traditional cleaners, the product is a butyl-free, VOC-compliant solution that targets pet stains and odors at the molecular level.

Delivers 13th Consecutive Quarter of Gross Originations Growth Pending Merger Transaction with The Aaron’s Company and CCF Holdings LLC Expected to Create a Premier Omnichannel Platform for Nonprime Consumers  

BROOKLYN, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Voyager Acquisition Corporation (NASDAQ: “VACHU,” “VACH,” “VACHW”) (“Voyager” or the “Company”) today announced that holders of 25,217,315 of the Company's Class A ordinary shares (“Class A shares”) exercised their right to redeem their shares for a pro rata portion of the funds in the Company's trust account, reflecting redemptions of approximately 99.67% of the total Class A shares outstanding in connection with the completion of the Company’s business combination (the “Business Combination”) pursuant to the business combination agreement between the Company, VERAXA Biotech AG (“VERAXA”) and the other parties thereto (the “Business Combination Agreement”). The 25,217,315 Class A shares which were submitted for redemption have not been withdrawn and will accordingly be redeemed pursuant to the option to redeem provided to holders of the Company’s Class A shares. As a result, assuming redemption elections are not withdrawn or reversed, following the effectuation of redemptions approximately $885,556 will remain in the Company's trust account and 82,685 Class A shares will convert into shares of VERAXA Biotech Holding AG.

BEIJING, March 11, 2026 (GLOBE NEWSWIRE) -- Yuanbao Inc. (“Yuanbao” or the “Company”) (NASDAQ: YB), a leading technology-driven online insurance distributor in China, today announced that it will release its fourth quarter and fiscal year 2025 unaudited financial results on Wednesday, March 18, 2026, before the open of the U.S. markets.

Project Designed to Supply ~50% of U.S. Natural Graphite Demand, Directly Addressing America’s 100% Import Reliance

First-of-its-kind study will follow AI-native children and families for generations to understand how AI reshapes learning, health, work, and civic life

Earnings Call Scheduled for 8:30 a.m. U.S. Eastern Time on Wednesday, March 18, 2026

Heidelberg, Germany, March 11, 2026 – TolerogenixX, a clinical-stage biopharmaceutical company developing personalized cell therapies to induce sustained immune tolerance in organ transplantation and autoimmune diseases, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its lead cell therapy candidate MIC-Lx for individualized immuno-suppression in living donor kidney transplantation. The PRIME scheme supports medicines addressing serious diseases with significant unmet medical need and provides early and enhanced regulatory interaction with the EMA to accelerate clinical development and patient access.

BEIJING, March 11, 2026 (GLOBE NEWSWIRE) -- 36Kr Holdings Inc. (“36Kr” or the “Company”) (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced that it will report its second half and fiscal year 2025 unaudited financial results, on Tuesday, March 17, 2026, before the open of U.S. markets.

SHENZHEN, China, March 11, 2026 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025, before the U.S. market opens on Thursday, March 19, 2026.

Stellantis Announces Pricing of Hybrid Bonds Offering

VICTORIA, Seychelles, March 11, 2026 (GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), today announced a strategic partnership with B2C2, a global leader in institutional digital asset trading. The collaboration brings B2C2's deep, reliable liquidity and execution capabilities to Bitget's institutional ecosystem.

PRESS RELEASE

PRESS RELEASE

New York, NY, March 11, 2026 (GLOBE NEWSWIRE) -- Propr®, the fluoride free oral care brand founded by leading periodontist and educator Dr. Jack Gruber, today announced the launch of Propr Paste, the third product in the Propr family and a key milestone in the brand’s mission to redefine everyday oral hygiene through gentler, smarter design.

Highlights

$250,000 top award goes to Connor Hill in America’s longest running and most distinguished science and math competition

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 1, 2026 to file lead plaintiff applications in a securities class action lawsuit against Apollo Global Management, Inc. (NYSE: APO) (“Apollo” or the “Company”), if they purchased or otherwise acquired the Company’s securities between May 10, 2021 and February 21, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced the pricing of its upsized underwritten public offering of 10,526,317 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 877,194 common shares pursuant to its existing shelf registration statement. The common shares are being offered at a public offering price of $57.00 per common share and the pre-funded warrants are being offered at a price of $56.9999 per pre-funded warrant. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, are expected to be approximately $650.0 million. In addition, Xenon has granted to the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,710,526 common shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about March 12, 2026, subject to the satisfaction of customary closing conditions.

NEW YORK CITY and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Navan, Inc. (“Navan” or the “Company”) (NasdaqGS: NAVN) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NasdaqCM: SLNO) of a class action securities lawsuit.

NEW YORK CITY and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in CoreWeave, Inc. (“CoreWeave” or the “Company”) (NasdaqGS: CRWV) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Enphase Energy, Inc. (“Enphase” or the “Company”) (NasdaqGM: ENPH) of a class action securities lawsuit.

NEW YORK CITY and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD) of a class action securities lawsuit.

MONTRÉAL, March 10, 2026 (GLOBE NEWSWIRE) -- Transcontinental Inc. (TSX: TCL.A TCL.B) held its Annual and Special Meeting of Shareholders today. All of the candidates proposed as directors were elected and all other resolutions were approved by the applicable majority of the votes cast by the shareholders present or represented by proxy at the meeting by secret ballot as follows:

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 21, 2026 to file lead plaintiff applications in a securities class action lawsuit against Corcept Therapeutics Incorporated (NasdaqCM: CORT) (“Corcept” or the “Company”), if they purchased or otherwise acquired the Company’s shares between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until March 23, 2026 to file lead plaintiff applications in a securities class action lawsuit against BellRing Brands, Inc. (NYSE: BRBR), if they purchased or otherwise acquired the Company’s securities between November 19, 2024 and August 4, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

NEW YORK and NEW ORLEANS, March 10, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

DALLAS, March 10, 2026 (GLOBE NEWSWIRE) -- Kosmos Energy Ltd. (“Kosmos” or the “Company”) (NYSE/LSE:KOS) announced today the pricing of its registered underwritten public offering of 97,500,000 shares of common stock (the “Offering”) at a price to the public of $1.90, resulting in gross proceeds to Kosmos of $185,250,000. In addition, Kosmos has granted the underwriters a 30-day option to purchase up to an additional 14,625,000 shares of common stock at the public offering price less underwriting discounts. The Offering is expected to close on March 12, 2026, subject to customary closing conditions.

MONTREAL, March 10, 2026 (GLOBE NEWSWIRE) -- Transcontinental Inc. (TSX: TCL.A TCL.B) ("TC Transcontinental" or the "Corporation") is pleased to announce that, in connection with the closing of the sale of the Corporation’s Packaging Sector to ProAmpac Holdings Inc. and certain of its subsidiaries, as previously announced on March 6, 2026, the Board of Directors of the Corporation has authorized a special cash distribution of $20.00 (the “Distribution”) per Class A Subordinate Voting Share (the "Class A Shares") and Class B Share (the "Class B Shares"), to be effected by: (i) a reduction of stated capital of approximately $7.00 per Class A Share, and (ii) a cash dividend for the balance of the Distribution. The Distribution will be payable on Friday, March 20, 2026 (the “Payment Date”), to shareholders of record holding Class A Shares and Class B Shares as of March 18, 2026 (the “Record Date”).

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Navan, Inc. (NASDAQ:NAVN) and Corcept Therapeutics Incorporated (NASDAQ:CORT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ostin Technology Group Co., Ltd. (NASDAQ:OST) and NuScale Power Corporation (NYSE:SMR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Las Vegas, Nevada, March 10, 2026 (GLOBE NEWSWIRE) -- SUMA Acquisition Corporation (NASDAQ: SUMAU) (the “Company”) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. The Company's units will be listed on the Nasdaq Global Market under the symbol “SUMAU” and is expected to begin trading on March 11, 2026. Each unit issued in the offering consists of one Class A ordinary share of the Company and one right to receive one-fifth (1/5) of a Class A ordinary share upon the consummation of the Company’s initial business combination. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to be listed on NASDAQ under the symbols “SUMA” and “SUMAR,” respectively. The closing of the offering is anticipated to take place on or about March 12, 2026, subject to customary closing conditions.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Boston Scientific (BSX) To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In monday.com To Contact Him Directly To Discuss Their Options

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Lakeland Industries, Inc. (NASDAQ:LAKE) and Zynex, Inc. (OTCPK: ZYXIQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) --

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) --

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) --

Sen. Shelley Moore Capito and Rep. Paul D. Tonko to Receive GLOBAL’s Highest Honor; Award-Winning Journalists Kyra Phillips & John Roberts to Emcee

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) --

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) --

Freeland, MI, March 10, 2026 (GLOBE NEWSWIRE) -- MBS International Airport, in partnership with Veregy, is proud to announce the nearing completion of its landmark $2.3 million solar energy project. This multi-phase initiative has officially established MBS as a leader in aviation sustainability, recently earning the prestigious title of “Michigan Department of Transportation (MDOT) Commercial Airport of the Year.”

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.

The Campaign More Than Doubled Its Original Goal

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CoreWeave (CRWV) To Contact Him Directly To Discuss Their Options

SANTA CLARA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco”), a provider of AI enabled TCAD and EDA solutions, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, announces the immediate availability of MixelTM, MIPI® “Production Ready Offerings,” or Mixel MIPI “PRO IP”. This announcement reinforces Silvaco’s commitment to providing silicon-proven, high-performance connectivity solutions with outstanding customer service, building on its reputation for "Mixed-Signal Excellence."

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of HF Sinclair Corporation (“HF Sinclair” or the “Company”) (NYSE: DINO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LIMASSOL, Cyprus, March 10, 2026 (GLOBE NEWSWIRE) -- Robin Energy Ltd. (NASDAQ: RBNE) ("Robin Energy", “Robin” or the "Company"), an international ship-owning company providing energy transportation services globally, announces that its Board of Directors (the "Board") has decided, at the recommendation of its special committee of disinterested and independent directors, to effect a spin-off of its tanker business comprising of one tanker and Xavier Shipping Co. (subsidiary formerly owning the M/T Wonder Formosa), and cash (the “Spin-Off”). In the Spin-Off, Robin shareholders will receive one common share of AI OKTO CORP. (“AI OKTO”), a newly formed subsidiary that will act as the holding company for the one tanker vessel, for every 6.5 Robin common shares. AI OKTO has applied to have its common shares listed on the Nasdaq Capital Market. Robin’s Chairman and Chief Executive Officer, Petros Panagiotidis, has been appointed as Chairman and Chief Executive Officer of AI OKTO with effect as of the completion of the Spin-Off.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Northern Dynasty Minerals Ltd. (“Northern Dynasty” or the “Company”) (NYSE: NAK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Coty Inc. (“Coty” or the “Company”) (NYSE: COTY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Planet Fitness, Inc. (“Planet Fitness” or the “Company”) (NYSE: PLNT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

New York, NY, March 10, 2026 (GLOBE NEWSWIRE) -- The New York Film Academy (NYFA) proudly celebrates the achievements of its faculty and alumni whose creative talents are showcased in multiple films featured at the South by Southwest festival (SXSW) this year. Among the selected projects are Imposters, Are We Still Married?, and Anima, films that highlight the diverse storytelling, technical skill, and collaborative spirit cultivated within the NYFA community. 

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Helen of Troy Limited (“Helen of Troy” or the “Company”) (NASDAQ: HELE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Upstart Holdings, Inc. (“Upstart” or the “Company”) (NASDAQ: UPST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Marriott Vacations Worldwide Corporation (“Marriott Vacations” or the “Company”) (NYSE: VAC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alight, Inc. (“Alight” or the “Company”) (NYSE: ALIT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.